Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

Autores
Lamberti, María Julia; Nigro, Annunziata; Mentucci, Fátima María; Rumie Vittar, Natalia Belen; Casolaro, Vincenzo; Dal Col, Jessica
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.
Fil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Nigro, Annunziata. Universita di Salerno; Italia
Fil: Mentucci, Fátima María. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Rumie Vittar, Natalia Belen. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Casolaro, Vincenzo. Universita di Salerno; Italia
Fil: Dal Col, Jessica. Universita di Salerno; Italia
Materia
CANCER TREATMENT
DENDRITIC CELL-BASED VACCINATION
IMMUNOGENIC CELL DEATH
IMMUNOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/143975
Acceder
id CONICETDig_fc16ec2b9f31aa116aaea793e391512b
oai_identifier_str oai:ri.conicet.gov.ar:11336/143975
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor ImmunityLamberti, María JuliaNigro, AnnunziataMentucci, Fátima MaríaRumie Vittar, Natalia BelenCasolaro, VincenzoDal Col, JessicaCANCER TREATMENTDENDRITIC CELL-BASED VACCINATIONIMMUNOGENIC CELL DEATHIMMUNOTHERAPYhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.Fil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; ArgentinaFil: Nigro, Annunziata. Universita di Salerno; ItaliaFil: Mentucci, Fátima María. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; ArgentinaFil: Rumie Vittar, Natalia Belen. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; ArgentinaFil: Casolaro, Vincenzo. Universita di Salerno; ItaliaFil: Dal Col, Jessica. Universita di Salerno; ItaliaMDPI2020-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/143975Lamberti, María Julia; Nigro, Annunziata; Mentucci, Fátima María; Rumie Vittar, Natalia Belen; Casolaro, Vincenzo; et al.; Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity; MDPI; Pharmaceutics; 12; 3; 3-2020; 1-281999-4923CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1999-4923/12/3/256info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics12030256info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:47:48Zoai:ri.conicet.gov.ar:11336/143975instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:47:49.03CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
title Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
spellingShingle Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
Lamberti, María Julia
CANCER TREATMENT
DENDRITIC CELL-BASED VACCINATION
IMMUNOGENIC CELL DEATH
IMMUNOTHERAPY
title_short Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
title_full Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
title_fullStr Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
title_full_unstemmed Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
title_sort Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
dc.creator.none.fl_str_mv Lamberti, María Julia
Nigro, Annunziata
Mentucci, Fátima María
Rumie Vittar, Natalia Belen
Casolaro, Vincenzo
Dal Col, Jessica
author Lamberti, María Julia
author_facet Lamberti, María Julia
Nigro, Annunziata
Mentucci, Fátima María
Rumie Vittar, Natalia Belen
Casolaro, Vincenzo
Dal Col, Jessica
author_role author
author2 Nigro, Annunziata
Mentucci, Fátima María
Rumie Vittar, Natalia Belen
Casolaro, Vincenzo
Dal Col, Jessica
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv CANCER TREATMENT
DENDRITIC CELL-BASED VACCINATION
IMMUNOGENIC CELL DEATH
IMMUNOTHERAPY
topic CANCER TREATMENT
DENDRITIC CELL-BASED VACCINATION
IMMUNOGENIC CELL DEATH
IMMUNOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.
Fil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Nigro, Annunziata. Universita di Salerno; Italia
Fil: Mentucci, Fátima María. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Rumie Vittar, Natalia Belen. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Fil: Casolaro, Vincenzo. Universita di Salerno; Italia
Fil: Dal Col, Jessica. Universita di Salerno; Italia
description The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.
publishDate 2020
dc.date.none.fl_str_mv 2020-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/143975
Lamberti, María Julia; Nigro, Annunziata; Mentucci, Fátima María; Rumie Vittar, Natalia Belen; Casolaro, Vincenzo; et al.; Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity; MDPI; Pharmaceutics; 12; 3; 3-2020; 1-28
1999-4923
CONICET Digital
CONICET
url http://hdl.handle.net/11336/143975
identifier_str_mv Lamberti, María Julia; Nigro, Annunziata; Mentucci, Fátima María; Rumie Vittar, Natalia Belen; Casolaro, Vincenzo; et al.; Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity; MDPI; Pharmaceutics; 12; 3; 3-2020; 1-28
1999-4923
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1999-4923/12/3/256
info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics12030256
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082995693289472
score 13.22299

Publicaciones similares